Temodar clinical trials
Temodar is named as an intervention in 22 current clinical trials in our Canada, Australia, USA, France, Israel, Netherlands, Spain, Italy, Germany, Switzerland, Mexico, UK, Czechia, Norway, Belgium and Denmark registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Children's Oncology Group (3). The most-studied condition is Glioblastoma.
Patient leaflets for Temodar
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Temodar
22 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Temodar
35 conditionsAll 35 conditions
| Condition (as registered) | Trials |
|---|---|
| Glioblastoma | 8 |
| Neuroblastoma | 3 |
| Glioblastoma Multiforme | 3 |
| Glioblastoma (GBM) | 2 |
| GBM | 2 |
| Ganglioneuroblastoma, Nodular | 2 |
| Gliosarcoma | 2 |
| Advanced or Metastatic NRAS-mutant Melanoma | 1 |
| Melanoma, Cutaneous Malignant | 1 |
| Mucosal Melanoma | 1 |
| Newly Diagnosed Glioblastoma | 1 |
| Glioblastoma Multiforme (GBM) | 1 |
| Solid Tumors | 1 |
| Rhabdomyosarcoma | 1 |
| Ewing Sarcoma | 1 |
| Glioblastoma, IDH-wildtype | 1 |
| Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | 1 |
| Brain Neoplasms, Adult, Malignant | 1 |
| Brain Tumor | 1 |
| Brain and Central Nervous System Tumors | 1 |
| Pediatric Cancer | 1 |
| High Risk Neuroblastoma | 1 |
| Recurrent Neuroblastoma | 1 |
| Refractory Neuroblastoma | 1 |
| Recurrent Solid Tumor | 1 |
| Recurrent Ewing Sarcoma | 1 |
| Recurrent Hepatoblastoma | 1 |
| Recurrent Malignant Germ Cell Tumor | 1 |
| Anaplastic Astrocytoma | 1 |
| Malignant Glioma | 1 |
| Metastatic Malignant Neoplasm in the Liver | 1 |
| Pancreatic Neuroendocrine Tumor | 1 |
| Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
| Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
| Recurrent Glioblastoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Children's Oncology Group | 3 |
| NRG Oncology | 2 |
| Erasca, Inc | 1 |
| Immatics US, Inc | 1 |
| Black Diamond Therapeutics, Inc | 1 |
| Diakonos Oncology Corporation | 1 |
| Valent Technologies, LLC | 1 |
| Orbus Therapeutics, Inc | 1 |
| NeuGATE Theranostics | 1 |
| Ivy Brain Tumor Center | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Global Coalition for Adaptive Research | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| St. Jude Children's Research Hospital | 1 |
| National Cancer Institute (NCI) | 1 |
+ 4 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Temodar trials
How many clinical trials are testing Temodar?
22 current trials in our Canada, Australia, USA, France, Israel, Netherlands, Spain, Italy, Germany, Switzerland, Mexico, UK, Czechia, Norway, Belgium and Denmark registers name Temodar as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Temodar trials recruiting patients?
Yes. 9 of the 22 trials are recruiting: 4 with sites in Canada, 2 with sites in Australia, 4 with sites in USA, 3 with sites in France, 3 with sites in Israel, 2 with sites in Netherlands, 1 with sites in Spain, 1 with sites in Italy, 2 with sites in Germany, 1 with sites in Switzerland, 2 with sites in Mexico, 1 with sites in UK and 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Temodar clinical trials?
Children's Oncology Group (3), NRG Oncology (2), Erasca, Inc (1) and Immatics US, Inc (1), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Temodar works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Temodar works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Temodar (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.